Nordic Capital to partner with Minerva Imaging, supporting radiopharmaceutical growth
- Editor
- Jun 10
- 2 min read
Whats Happening:
Nordic Capital is investing in Minerva Imaging, a leading Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) specializing in targeted radioligand therapies. The partnership aims to accelerate Minerva's growth, international expansion, and strengthen its integrated platform and service offerings. The goal is to build a global market-leading radiopharmaceutical platform.
Key Moves:
Nordic Capital invests in Minerva Imaging to support growth in radiopharmaceutical sector
Partnership aims to accelerate Minerva's international expansion and strengthen service offerings
Investment to help build a global market-leading radiopharmaceutical platform
By The Numbers:
Minerva generated revenue of over DKK 225 million in 2024
Minerva employs over 150 highly skilled professionals
Nordic Capital Evolution has EUR 3.2 billion in total committed capital
Key Quotes:
"We are incredibly proud of Minerva's progress since its founding. Our innovative solutions are making a meaningful impact for our collaborators and customers, with the ultimate goal of helping patients," said Andreas Kjaer, Chairman and Founder, Minerva.
"Together with Nordic Capital, we can seek to support innovation and boost our growth via organic expansion and potential selective strategic acquisitions," said Carsten H. Nielsen, CEO and Founder, Minerva.
"As a leading healthcare investor with deep expertise across pharma, life sciences, and pharma services - and a strong track record in supporting international expansion - we are convinced Nordic Capital is uniquely positioned to support Minerva in its next phase of growth," said Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory.
Bottom Line:
Nordic Capital's investment in Minerva Imaging represents a significant move in the radiopharmaceutical sector. By leveraging Nordic Capital's expertise and capital, Minerva aims to accelerate its growth, expand internationally, and strengthen its service offerings. This partnership has the potential to create a global leader in the rapidly growing radiopharmaceutical market, which is expected to see significant growth over the next decade.
Comments